Literature DB >> 22227854

A study of PKM2, PFK-1, and ANT1 expressions in cervical biopsy tissues in China.

Yang Yuan1, Peng Guo-Qing, Tian Yan, Ying Hong-Lin, Hu Gong-Hua, Zhong Cai-Gao.   

Abstract

This present study explored the association of Pyruvate Kinase isozyme M2 (PKM2), Phosphofructokinase 1 (PFK-1) and Adenine nucleotide translocator 1 (ANT1) with cervical carcinoma. A case-control method was designed by the collected 95 cervical biopsy samples, which were divided into 30 controls and 60 cases. Cases were subdivided into mild cervical carcinoma (MCC-25), intermediate cervical carcinoma (ICC-20), and severe cervical carcinoma (SCC-20) by method of cervical pathology. The expression of PKM2, PFK-1, and ANT1 was examined by methods of immunohistochemistry and western blotting (WB). The results showed that the positive proportions of PKM2 and PFK-1 in case group were higher than that of control, and the increased positive proportions of PKM2 and PFK-1 were also revealed with the order of Control, MCC, ICC, SCC (P<0.05). Further, the results of WB confirmed the enhanced expressions of PKM2 and PFK-1 in case group and the increasing trend of PKM2 and PFK-1 expressions in Control, MCC, ICC, and SCC groups. In addition, the WB result of ANT1 showed a lower level of expression in SCC group, while the positive proportion of ANT1 was not significant between cases group and control. In conclusion, PKM2 and PFK-1 genes are associated closely with cervical carcinoma. The enhanced expressions of PKM2 and PFK-1 indicate one developing signal of cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22227854     DOI: 10.1007/s12032-011-0154-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

Review 1.  Different modes of activating phosphofructokinase, a key regulatory enzyme of glycolysis, in working vertebrate muscle.

Authors:  G Wegener; U Krause
Journal:  Biochem Soc Trans       Date:  2002-04       Impact factor: 5.407

2.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

3.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

4.  [Effect of changes in pH on intracellular Ca2+ and cell length of myocytes].

Authors:  Wei Liu; Yue-Lan Zhang; Jing-Quan Wang
Journal:  Zhongguo Ying Yong Sheng Li Xue Za Zhi       Date:  2002-08

5.  Reconstructing the mosaic glycolytic pathway of the anaerobic eukaryote Monocercomonoides.

Authors:  Natalia A Liapounova; Vladimir Hampl; Paul M K Gordon; Christoph W Sensen; Lashitew Gedamu; Joel B Dacks
Journal:  Eukaryot Cell       Date:  2006-10-27

6.  The mitochondrial adenine nucleotide translocator from Dictyostelium discoideum. Functional characterization and DNA sequencing.

Authors:  M Bof; G Brandolin; M Satre; G Klein
Journal:  Eur J Biochem       Date:  1999-02

7.  Apoptosis induced by IL-2 withdrawal is associated with an intracellular acidification.

Authors:  A Rebollo; J Gómez; A Martínez de Aragón; P Lastres; A Silva; D Pérez-Sala
Journal:  Exp Cell Res       Date:  1995-06       Impact factor: 3.905

Review 8.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

9.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

10.  Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.

Authors:  Babita Kaura; Rashmi Bagga; Feruza D Patel
Journal:  J Obstet Gynaecol Res       Date:  2004-06       Impact factor: 1.730

View more
  7 in total

1.  M2 isoform of pyruvate kinase (PKM2) is upregulated in Kazakh's ESCC and promotes proliferation and migration of ESCC cells.

Authors:  Qing Liu; Meng Liang; Tao Liu; Lucine Vuitton; Shutao Zheng; Xiangpeng Gao; Mang Lu; Xiuling Li; Ilyar Sheyhidin; Xiaomei Lu
Journal:  Tumour Biol       Date:  2015-09-24

2.  LincRNA-p21 suppresses development of human prostate cancer through inhibition of PKM2.

Authors:  Xiaohai Wang; Yongzhi Xu; Xingjie Wang; Chenyi Jiang; Sha Han; Kai Dong; Mengjun Shen; Dongliang Xu
Journal:  Cell Prolif       Date:  2017-10-09       Impact factor: 6.831

3.  Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis.

Authors:  Haiyan Zhu; Hui Luo; Xuejie Zhu; Xiaoli Hu; Lihong Zheng; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-01-03

4.  Knockdown of PKM2 suppresses tumor progression in human cervical cancer by modulating epithelial-mesenchymal transition via Wnt/β-catenin signaling.

Authors:  Yanzhu Lin; Fanqing Meng; Zhiyuan Lu; Kai Chen; Yalan Tao; Yi Ouyang; Xinping Cao
Journal:  Cancer Manag Res       Date:  2018-10-04       Impact factor: 3.989

5.  The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.

Authors:  He Xiaoyu; Yin Yiru; Shi Shuisheng; Cheng Keyan; Yan Zixing; Cheng Shanglin; Wang Yuan; Cheng Dongming; Zhang Wangliang; Bai Xudong; Ma Jie
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

6.  Effects of GPR81 silencing combined with cisplatin stimulation on biological function in hypopharyngeal squamous cell carcinoma.

Authors:  Qiaojing Jia; Ou Xu; Jianxing Wang; Jinhui Dong; Xiumin Ren; Xiaofang Jia; Chunguang Shan
Journal:  Mol Med Rep       Date:  2020-06-18       Impact factor: 2.952

7.  PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.

Authors:  Haiyan Zhu; Jun Wu; Wenwen Zhang; Hui Luo; Zhaojun Shen; Huihui Cheng; Xueqiong Zhu
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.